Correction of hemodialysis anemia is associated with significant increase in serum concentration of IGF-I in patients treated with Eeythropoietin: A randomized controlled study

International Urology and Nephrology

Volumn 37, Issue 1, 2005, Pages 153-158

  Sheashaa, Hussein A ^a   Khalil, Abdalla ^a   Aarman, Mohammed M ^b   El Shahat, Fagr B ^b   Selim, Amal ^b   El Gawad, Soma Sherif ^b  

^a MANSOURA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Erythropoietin; Hemodialysis anemia; Insulin like growth factor I

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON; SOMATOMEDIN C;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIET THERAPY; DRUG DOSE REGIMEN; DRUG EFFECT; ERYTHROPOIESIS; FEMALE; GLOMERULONEPHRITIS; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; KIDNEY POLYCYSTIC DISEASE; LABORATORY TEST; MALE; NUTRITIONAL STATUS; PROTEIN BLOOD LEVEL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS;

ADULT; ANEMIA; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; HEMATOCRIT; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 24144480588     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-004-2360-5     Document Type: Article

References (20)

1. AJ. Collins 2003 Anemia management prior to dialysis: Cardiovascular and cost benefit observations Nephrol Dial Transplant 18 S2 2-6 10.1093/ndt/ gfg1032
2. AJ Collins S Li W St Peter J Ebben T Roberts JZ Ma W. Manning 2001 Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36%-39% J Am Soc Nephrol 12 2465-2473 11675424
3. A Besarab CM Reyes J. Hornberger 2002 Meta-analysis of subcutaneous versus intravenous EPO in maintenance treatment of anemia in hemodialysis patients Am J Kidney Dis 40 3 439-446 10.1053/ ajkd.2002.34881 12200793
4. JL Jones DR. Clemmons 1995 Insulin-like growth factors and their binding proteins: Biological actions Endocr Rev 16 1 3-34 10.1210/er.16.1.3 7758431
5. S Miyagawa M Kobayashi N Konishi T Sato et al. 2000 Insulin and insulin-like growth factor I support the proliferation of erythroid progenitor cells in bone marrow through the sharing of receptors Br J Haematol 109 3 555-562 10.1046/j.1365-2141.2000.02047.x 10886204
6. JT Daugirdas TA. Depner 1994 A nomogram approach to hemodialysis urea modeling Am J Kidney Dis 23 1 33-40 8285195
7. WH Daughaday P. Rotwein 1989 Insulin-like growth factor-I and II. Peptides, messenger ribonucleic acid and gene structure, serum and tissue concentrations Endocrine Rev 10 1 68-91
8. P Urena A Bonnardeaux KU Eckardt A Kurtz et al. 1992 Insulin-like growth factor I: A modulator of erythropoiesis in uraemic patients? Nephrol Dial Transplant 7 1 40-44 1316579
9. S. Merchav 1998 The haematopoietic effects of growth hormone and insulin-like growth factor I J Pediatr Endocrinol Metab 11 6 677-685 9829220
10. G Ramirez PA Bittle H Sanders HA Rabb et al. 1994 The effects of corticotropin and growth hormone releasing hormones on their respective secretory axes in chronic hemodialysis patients before and after correction of anemia with recombinant human erythropoietin J Clin Endocrinol Metab 78 1 63-69 10.1210/jc.78.1.63 8288716
11. MJ Fernandez-Reyes F Alvarez-Ude R Sanchez C Mon P Iglesias JJ Diez A. Vazquez 2002 Inflammation and malnutrition as predictors of mortality in patients on hemodialysis J Nephrol 15 2 136-143 12018629
12. N Besbas F Ozaltin T Coskun Ozalp et al. 2003 Relationship of leptin and insulin-like growth factor I to nutritional status in hemodialyzed children Pediatr Nephrol. 18 12 1255-1259 10.1007/s00467-003-1264-4 14586683
13. M Sohmiya Y. Kato 2001 Effect of long-term administration of recombinant human growth hormone (rhGH) on plasma erythropoietin (EPO) and hemoglobin levels in anemic patients with adult GH deficiency Clin Endocrinol (Oxf) 55 6 749-754 10.1046/j.1365-2265.2001.01417.x
14. LY Shih JY Huang CT. Lee 1999 Insulin-like growth factor I plays a role in regulating erythropoiesis in patients with end-stage renal disease and erythrocytosis J Am Soc Nephrol. 10 2 315-322 10.1159/000017161 10215331
15. J Malyszko S Wolczynski E Zbroch S Brzosko et al. 2002 Insulin-like growth factor system components in relation to erythropoietin therapy and bone metabolism in dialyzed patients and kidney transplant recipients Nephron 90 3 282-289 10.1159/000049064 11867949
16. JF Navarro C Mora M Macia J. Garcia 2002 Randomized prospective comparison between EPO and androgens in CAPD patients Kidney Int 61 4 1537-1544 10.1046/j.1523-1755.2002.00271.x 11918762
17. HE Carlson ML Graber MC Gelato JM. Hershman 1995 Endocrine effects of erythropoietin Int J Artif Organs 18 6 309-314 8593965
18. M Matsumura H Nomura I Koni H. Mabuchi 1997 Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialysis patients Nephron 77 2 164-168 9346382
19. S Albitar R Genin M Fen-Chong MO Serveaux B. Bourgeon 1998 High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients Nephrol Dial Transplant 13 5 1206-1210 10.1093/ ndt/13.5.1206 9623555
20. LF Morrone S Di Paolo F Logoluso A Schena et al. 1997 Interference of angiotensin converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: Role of growth factors and cytokines Transplantation 64 6 913-918 10.1097/00007890-199709270-00021 9326420